Keith A. Goldan Syndax Pharmaceuticals Inc (SNDX) insider trading activity

Keith A. Goldan is Chief Financial Officer of Syndax Pharmaceuticals Inc. Currently has a direct ownership of 90,746 shares of SNDX, which is worth approximately $1.49 Million. The most recent transaction as insider was on Feb 10, 2025, when has been sold 3,777 shares (Common Stock) at a price of $15.5 per share, resulting in proceeds of $58,543. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 90.7K

72.45% 3M change

76.64% 12M change

Total Value Held $1.49 Million

Keith A. Goldan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 10 2025	SELL Open market or private sale	$58,543 $15.5 p/Share	3,777 Reduced 4.0%	90,746 Common Stock
Feb 05 2025	BUY Grant, award, or other acquisition	-	41,900 Added 30.71%	94,523 Common Stock
Jun 14 2024	BUY Open market or private purchase	$25,037 $20.03 p/Share	1,250 Added 2.32%	52,623 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	46,700 Added 47.62%	51,373 Common Stock
Jan 31 2024	BUY Other acquisition or disposition	$20,607 $17.42 p/Share	1,183 Added 20.2%	4,673 Common Stock
Jul 31 2023	BUY Other acquisition or disposition	$15,619 $18.12 p/Share	862 Added 19.81%	3,490 Common Stock
Jun 13 2023	SELL Open market or private sale	$12,872 $22.31 p/Share	577 Reduced 18.0%	2,628 Common Stock
Jun 13 2022	BUY Grant, award, or other acquisition	-	3,205 Added 50.0%	3,205 Common Stock

Also insider at

OPTN

OptiNose, Inc. Healthcare

Chief Financial Officer

KAG

Keith A. Goldan

Chief Financial Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SNDX shares.

Notify only if

Value

Insider Trading

Get notified when an Syndax Pharmaceuticals Inc insider buys or sells SNDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Syndax Pharmaceuticals Inc

Track Activities on SNDX

Account